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Commensal gut microflora and dietary fiber protect
against colonic inflammation and colon cancer
through unknown targets. Butyrate, a bacterial prod-
uct from fermentation of dietary fiber in the colon, has
been implicated in this process. GPR109A (encoded
by Niacr1) is a receptor for butyrate in the colon.
GPR109A is also a receptor for niacin, which is also
produced by gut microbiota and suppresses intes-
tinal inflammation. Here we showed that Gpr109a
signaling promoted anti-inflammatory properties in
colonicmacrophagesanddendritic cells andenabled
them to induce differentiation of Treg cells and
IL-10-producing T cells. Moreover, Gpr109a was
essential for butyrate-mediated induction of IL-18
in colonic epithelium. Consequently, Niacr1/ mice
were susceptible to development of colonic inflam-
mation and colon cancer. Niacin, a pharmacological
Gpr109a agonist, suppressed colitis and colon can-
cer in a Gpr109a-dependent manner. Thus, Gpr10a
has an essential role in mediating the beneficial
effects of gut microbiota and dietary fiber in colon.
INTRODUCTION
Commensal microbiota in the gut have profound effects on hu-
man health (Ba¨ckhed et al., 2005; Honda and Littman, 2012).
Germ-free and antibiotic-treated mice are more susceptible to
dextran sulfate sodium (DSS)-induced colonic inflammation
(Maslowski et al., 2009; Rakoff-Nahoum et al., 2004). Bacter-
oides fragilis andClostridium clusters IV and XIVa protect against
trinitrobenzenesulfonic acid- or DSS-induced colitis (Atarashi
et al., 2011;Mazmanian et al., 2008). Multiple intestinal neoplasia
(Min, ApcMin/+) mice carry a germline-truncating mutation in
one copy of Apc and spontaneoulsy develop adenomas
throughout the intestinal tract. Lactobacillus acidophilus and128 Immunity 40, 128–139, January 16, 2014 ª2014 Elsevier Inc.certain gut microbial metabolites such as conjugated linoleic
acids decrease intestinal tumorigenesis in ApcMin/+ mice (Davis
and Milner, 2009; Urbanska et al., 2009). In contrast, depletion
of microbiota ameliorates intestinal inflammation and cancer
in mouse models of spontaneous colitis (Il10/, Tbx21/
Rag2/, or ApcMin/+) (Garrett et al., 2009; Grivennikov et al.,
2012; Li et al., 2012; Uronis et al., 2009).Bacteroides fragilis toxin
(BFT) and Bacteroides vulgatus increases inflammation and
colon cancer in ApcMin/+ and Il10/ mice, respectively (Uronis
et al., 2009; Wu et al., 2009). Thus, commensal bacteria promote
as well as suppress colonic inflammation and colon cancer in a
context-dependent manner.
One of the mechanisms by which gut microbiota promote
colonic health is through production of the short-chain fatty
acids (SCFAs) acetate, propionate, and butyrate by fermenta-
tion of dietary fiber. Among SCFAs, butyrate has received
most attention for its effects on colonic health (Hamer et al.,
2008). The functions of butyrate in promoting colonic health
range from being energy source for colonocytes to being a
key mediator of anti-inflammatory and antitumorigenic effects.
Gut microbiome analysis has revealed a significant decrease
in the number of butyrate-producing bacteria in colon of
patients with ulcerative colitis and colon cancer (Frank et al.,
2007; Wang et al., 2012). Colonic irrigation with butyrate sup-
presses inflammation during ulcerative colitis (Hamer et al.,
2008).
IL-10 deficiency leads to spontaneous colitis (Huber et al.,
2011; Izcue et al., 2009; Rubtsov et al., 2008). Polymorphisms
in the genes that encode IL-10 or IL-10 receptor are linked to
increased incidence of ulcerative colitis and inflammatory bowel
disease (Franke et al., 2008; Glocker et al., 2009). Human mono-
cyte-derived dendritic cells (DCs), whenmatured in the presence
of butyrate, have increased expression of IL-10 and decreased
production of IL-6 (Millard et al., 2002; Wang et al., 2008). IL-
18 plays an essential role in suppression of colonic inflamma-
tion and inflammation-associated cancers (Chen et al., 2011;
Dupaul-Chicoine et al., 2010; Elinav et al., 2011; Salcedo et al.,
2010; Zaki et al., 2010). Moreover, an IL-18 gene promoter poly-
morphism leading to decreased expression is found at higher
frequency in patients with ulcerative colitis (Takagawa et al.,
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(Kalina et al., 2002). In addition, the G protein-coupled receptor
43 (Gpr43) mediates proliferation of colonic regulatory T (Treg)
cells in response to exogenously administered SCFAs but not
under steady-state conditions (Smith et al., 2013). Although
these studies demonstrate that SCFAs serve as anti-inflamma-
tory agents in the colon, the underlying molecular mechanisms
remain poorly understood.
The most widely studied function of butyrate is its ability to
inhibit histone deacetylases. However, cell surface receptors
have been identified for butyrate; these receptors, GPR43 and
GPR109A (also known as hydroxycarboxylic acid receptor 2 or
HCA2), are G protein coupled and are expressed in colonic
epithelium, adipose tissue, and immune cells (Blad et al., 2012;
Ganapathy et al., 2013). GPR43-deficient mice undergo severe
colonic inflammation and colitis in DSS-induced colitis model
and the GPR43 agonist acetate protects germ-free mice from
DSS-induced colitis (Maslowski et al., 2009). Although GPR43
is activated by all three SCFAs, GPR109A (encoded by Niacr1)
is activated only by butyrate (Blad et al., 2012; Taggart et al.,
2005). GPR109A is also activated by niacin (vitamin B3) (Blad
et al., 2012; Ganapathy et al., 2013). In colonic lumen, butyrate
is generated at high concentrations (10–20 mM) by gut micro-
biota and serves as an endogenous agonist for GPR109A (Than-
garaju et al., 2009). We have shown that Gpr109a expression in
colon is induced by gutmicrobiota and is downregulated in colon
cancer (Cresci et al., 2010; Thangaraju et al., 2009). Gpr109a in
immune cells plays a nonredundant function in niacin-mediated
suppression of inflammation and atherosclerosis (Lukasova
et al., 2011). Gut microbiota also produce niacin. Niacin defi-
ciency in humans results in pellagra, characterized by intestinal
inflammation, diarrhea, dermatitis, and dementia (Hegyi et al.,
2004). It is of great clinical relevance that lower abundance of
GPR109A ligands niacin and butyrate in gut is associated with
colonic inflammation.
Here we demonstrate an anti-inflammatory and anticancer
function for Gpr109a in colon. Gpr109a signaling imposed anti-
inflammatory properties in colonic antigen-presenting cells,
which in turn induced differentiation of Treg cells and IL-10-pro-
ducing T cells. Gpr109a was also required for the expression of
IL-18. Niacr1/ mice showed enhanced susceptibility to colitis
and colon cancer. Depletion of gut microbiota or dietary fiber
increased the risk for colitis and cancer, which is effectively sup-
pressed by niacin in a Gpr109a-dependent manner.
RESULTS
Gpr109a Signaling Regulates Treg and IL-10-Producing
CD4+ T Cell Frequency in the Colon
We hypothesized that GPR109A has an anti-inflammatory role in
the colon. Because Treg cells are potent anti-inflammatory cells,
we studied the status of Treg cells in colons of mice lacking
Gpr109a. Colonic lamina propria (LP) of Niacr1/ mice harbor
significantly reduced (40%) frequency and number of Foxp3+
(Treg) cells among CD4+ cells than do LP of WT mice (Figures
1A and 1B; Figure S1A available online). In contrast, a similar fre-
quency of Treg cells was present among splenic and small intes-
tinal CD4+ T cells from both WT and Niacr1/ mice, suggesting
that reduction in Treg cells is specific to colon in Niacr1/ mice(Figures 1A, 1B, S1B, and S1C). CD4+ T cells producing IL-10
were also significantly reduced in colonic LP of Niacr1/ mice
compared to those from WT mice (Figures 1C and 1D). In
contrast, the frequency and number of CD4+ T cells producing
inflammatory cytokine IL-17 were elevated in colonic LP of
Niacr1/ mice compared to that of WT mice (Figures 1E, 1F,
and S1D). Similar fractions of splenic CD4+ T cells produced
IL-17 or IL-10 in both WT and Niacr1/ mice, suggesting that
the proinflammatory phenotype of CD4+ T cells in Niacr1/
mice was specific to colonic LP.
Colonic DCs and Macrophages from Niacr1–/– Mice
Are Defective in Inducing Differentiation of Treg and
IL-10-Producing CD4+ T Cells
To gain insight into the mechanism of reduced Treg and IL-10-
producing CD4+ T cells in colons of Niacr1/ mice, first we
evaluated the expression of Gpr109a by various immune cells.
Niacr1 mRNA is expressed by adipocytes and innate immune
cells (Gille et al., 2008). To determine its expression at the pro-
tein level, human peripheral blood mononuclear cells were
stained with an antibody specific to human GPR109A that
was expressed at highest levels in monocytes (Figure S2A).
Human blood DCs expressed lower but substantial amounts
of GPR109A. In contrast, T, B, and NK cells did not exhibit
detectable amounts of GPR109A. qPCR revealed similar
pattern of Niacr1 expression on mouse splenic T cells, B
cells, DCs, and macrophages (Figure S2B). Similarly, colonic
DCs, macrophages, and epithelium also expressed Gpr109a
(Figure S2B).
Because macrophages and DCs expressed Gpr109a and
because colonic DCs are critical in maintaining the balance
between Treg cells and IL-10- and IL-17-producing CD4+
T cells (Coombes et al., 2007; Manicassamy et al., 2010; Sun
et al., 2007), we reasoned that the proinflammatory phenotype
of colonic CD4+ T cells inNiacr1/mice is dependent on colonic
DCs and macrophages. Therefore, we tested the ability of mac-
rophages (CD45+I-Ab+CD11b+) and DCs (CD45+I-Ab+CD11c+)
isolated from colons ofWT andNiacr1/mice to promote differ-
entiation of naive CD4+ T cells from OT-II mice into Treg or Th17
cell lineage. Colonic DCs andmacrophages fromNiacr1/mice
were defective in inducing differentiation of naive OT-II CD4+
T cells into Treg cells (Figure 2A). In line with this, CD4+ T cells
primed with colonic DCs and macrophages from Niacr1/
mice produced reduced amount of IL-10 compared to those
primed with WT counterparts (Figure 2B). In contrast, colonic
DCs and macrophages from Niacr1/mice induced differentia-
tion of CD4+ T cells into cells producing higher amounts of the
inflammatory cytokine IL-17 compared to those from WT mice
(Figure 2B). CD103+ intestinal DCs express aldehyde dehydro-
genase (Aldh1a) and induce conversion of naive T cells into
Treg cells (Coombes et al., 2007; Sun et al., 2007). Similar fre-
quency of CD103+ cells was present among colonic DCs from
both WT and Niacr1/ mice (data not shown), ruling out the
possibility that reduced ability of Gpr109a-deficient colonic
DCs to induce conversion of naive T cells into Treg cells was
due to fewer number of CD103+ DCs. These data indicate
that colonic DCs and macrophages from Niacr1/ mice are
defective in inducing differentiation of naive T cells into Treg
and IL-10-producing T cells.Immunity 40, 128–139, January 16, 2014 ª2014 Elsevier Inc. 129
Figure 1. Proinflammatory Phenotype of
Colonic CD4+ T Cells from Niacr1–/– Mice
(A) Foxp3 expression by CD4+ T cells from colonic
lamina propria (LP) and spleens of WT and
Niacr1/ mice.
(B) Percent of Foxp3+ in CD4+ populations from
colonic LP and spleens of WT and Niacr1/ mice
(n = 3).
(C and E) IL-10 and IL-17 expression by PMA+
ionomycin-stimulated colonic LP and splenic
CD4+ T cells from WT and Niacr1/ mice.
(D and F) Quantification of IL-10- and IL-17-pro-
ducing CD4+ T cells shown in (C) and (E),
respectively (n = 3).
The numbers in (A), (C), and (E) represent per-
centage of positive cells in indicated area. Error
bars represent standard deviation (SD) of mean.
*p < 0.002. A representative of three independent
experiments is shown. See also Figure S1.
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Butyrate/Niacin Receptor Gpr109a in Colonic HealthButyrate- or Niacin-GPR109a Signaling Imparts Anti-
inflammatory Phenotype on DCs and Macrophages
Intestinal DCs and macrophages express anti-inflammatory
molecules such as IL-10 and Aldh1a that enable them to prefer-
entially favor differentiation of naive T cells into Treg cells and
suppress development of Th17 cells (Coombes et al., 2007;
Manicassamy et al., 2010; Sun et al., 2007). Niacr1/ colonic
DCs and macrophages were defective in expression of Aldh1a1
and IL-10 (Figure 2C). In contrast, expression of the proinflam-
matory cytokine IL-6, which induces differentiation of naive
CD4+ T cells into proinflammatory Th17 cells, was higher in
colonic APCs from Niacr1/ mice than in those from WT coun-
terparts (Figure 2C).
We hypothesized that butyrate, which is produced in colon by
gut microbiota and is an agonist for GPR109A, induces expres-
sion of IL-10 and Aldh1a1 in colonic macrophages and DCs in
a Gpr109a-dependent manner. For this, we cultured splenic
CD11c+ (DCs) and CD11b+ (macrophages) cells in the presence
or absence of butyrate and niacin and then analyzed the expres-
sion of Il10 and Aldh1a1. Both butyrate and niacin induced
expression of Il10 and Aldh1a1 by WT splenic DCs and macro-
phages (Figures 2D and S2C). In contrast, butyrate and niacin
failed to influence the expression levels of Il10 and Aldh1a1 in
Niacr1/ splenic DCs and macrophages. Consistent with this,130 Immunity 40, 128–139, January 16, 2014 ª2014 Elsevier Inc.WT splenic DCs and macrophages
treated with either butyrate or niacin
showed superior capability to induce dif-
ferentiation of naive T cells into Treg cells
than untreated counterparts (Figures 2E
and S2D). In addition, CD4+ T cells
primed with butyrate- or niacin-treated
WT splenic DCs or macrophages pro-
duced higher amounts of IL-10 and
reduced amounts of IL-17 (Figures S2E
and S2F). In contrast, treatment with
butyrate or niacin failed to affect the abil-
ity of Niacr1/ splenic DCs and macro-
phages to influence T cell differentiation
(Figures 2E and S2D–S2F).Antibiotic treatment reduces Treg cell numbers in colon (Atara-
shi et al., 2011; Smith et al., 2013). We tested whether niacin
induces Treg cells in antibiotic-treated mice in vivo. Compared
to control mice, antibiotic-treated WT mice had fewer Treg cells
in colon (Figures 2F and S2G). Niacin administration restored the
Tregcell number incolonsofantibiotic-treatedWTmice,butniacin
was ineffective in influencing the Treg cell number in Niacr1/
mice. To test the role of niacin and Gpr109a in antigen-specific
Treg cell induction in vivo, OT-II T cells were transferred into WT
orNiacr1/mice thatwere treatedwithantibiotics in thepresence
or absence of niacin, and the mice were fed the cognate antigen
ovalbumin in drinking water. Antibiotic treatment reduced
FoxP3+ T cells among OT-II CD4+ T cell population in WT mice.
Niacin increased Treg cells in adoptively transferred OT-II CD4+
T cells in colons of antibiotic-treatedWTmice, whereas the effect
of niacin to increaseTregcells in adoptively transferredOT-IICD4+
T cells was blunted in colons of Niacr1/ mice (Figure S2H).
Colonic macrophages and DCs promote Treg cell differentiation
via retinoic acid (RA); hence, RA receptor (RAR) antagonists inhibit
intestinal macrophage- or DC-induced conversion of naive T cells
into Treg cells. RAR antagonist LE135 completely abrogated
thebutyrate-orniacin-mediatedenhancementofTregcell conver-
sion by WT DCs (Figure S2I), indicating that butyrate or niacin in-
structs splenic DCs to acquire anti-inflammatory properties.
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Butyrate/Niacin Receptor Gpr109a in Colonic HealthButyrate or Niacin Induces IL-18 Expression in Colonic
Epithelium in a Gpr109a-Dependent Manner
Colons of germ-free (GF) mice expressed lower amount of Il18
mRNA than those of conventionally housed mice (Figure S3A).
Toll-like receptor (TLR) ligands do not influence Il18 expression
in the colon (Larsson et al., 2012), but butyrate does (Kalina
et al., 2002). To test the role of Gpr109a in butyrate-mediated in-
duction of Il18mRNA,we cultured neonatal colons fromWTmice
in the presence of butyrate and niacin for 1 day. Both butyrate
and niacin upregulated Il18 mRNA in neonatal colon organ cul-
tures (Figure S3B) but lipopolysaccharide did not (Figure S3B).
Butyrate- and niacin-mediated induction of Il18 mRNA in
neonatal colon was dependent on Gpr109a (Figure 3A). Expres-
sion of IL-18 in colonic epithelium protects colon against inflam-
mation and carcinogenesis in animal models (Dupaul-Chicoine
et al., 2010; Elinav et al., 2011; Salcedo et al., 2010). Therefore,
we analyzed the expression of IL-18 in colonic epithelium of
WT and Niacr1/ mice. Colonic epithelium from Niacr1/
mice contained significantly reduced amount of IL-18 mRNA
and protein compared to their WT counterparts (Figure 3B).
Next we tested the role of Gpr109a in butyrate- and niacin-
mediated induction of IL-18 mRNA in vivo. One day after admin-
istration of butyrate or niacin, colonic epithelium from WT
and Niacr1/ mice were tested for expression of IL-18. Both
butyrate and niacin induced expression of IL-18 in colonic
epithelium of WT mice but failed to do so in those of Niacr1/
mice (Figure 3C).
Gpr109a Deficiency Enhances Susceptibility to Lethal
Colitis and Colonic Inflammation
Because Gpr109a regulated the expression of IL-18, IL-10,
Aldh1a1, and the presence of Treg cells in colon, we examined
the role of Gpr109a in colonic inflammation. WT and Niacr1/
mice were subjected to 3% DSS in drinking water for 6 days
and their survival was monitored. Niacr1/ mice were highly
susceptible to this treatment and started dying on the 5th day
of DSS administration and all of them succumbed to death by
day 10 (Figure S4A). In contrast, all the WT mice were alive all
through the completion of the study.
To monitor both colonic inflammation and carcinogenesis in
a single model, we used a well-characterized mouse model of
inflammation-associated colon cancer in which DSS-mediated
injury induces inflammation that contributes to colon carcino-
genesis caused by azoxymethane (AOM). Mice were subjected
to intraperitoneal injection of AOM, followed by cyclic DSS
(2%) treatment (Figure 4A). We first evaluated the development
of colonic inflammation after the first cycle of DSS treatment.
Compared to WT mice, Niacr1/ mice showed severe weight
loss, diarrhea, and rectal bleeding and by day 15 they had lost
10% of body weight (Figures 4B–4D). After AOM+DSS treat-
ment, colons of Niacr1/ mice shrank and showed increased
weight per unit length compared to colons of WT mice (Fig-
ure S4B). Myeloperoxidase activity, a hallmark of colonic inflam-
mation, was upregulated in colons of Niacr1/ mice after
AOM+DSS treatment (Figure S4C). Colons from untreated WT
and Niacr1/ mice showed no morphological sign of damage
or inflammation. Colonic sections from AOM+DSS treatment
group revealed extensive damage to mucosa with epithelial
erosion and frequent ulcerations, loss of crypt structures, andinfiltration by immune cells in colons of Niacr1/ mice
compared to colons of similarly treated WT mice; this resulted
in a higher histological score (inflammation + epithelial damage)
in the former group (Figures 4E and S4D). Colons of Niacr1/
mice showed profoundly decreased staining for the tight junction
protein claudin-3 after treatment with AOM+DSS (Figure 4F),
indicating epithelial barrier breakdown. This was confirmed by
increased translocation of bacteria into liver and spleen, increase
in FITC-dextran in serum after oral gavage, and enhanced sys-
temic inflammation as shown by elevated levels of serum amy-
loid A, IL-6, IL-17, CCL2, IL-1b, and CXCL1 in the serum (Figures
S4E and S4F and data not shown).
Colons of unmanipulated Niacr1/ mice expressed reduced
amount of IL-10 compared to those ofWTmice. After AOM+DSS
treatment, colons of WT mice showed a modest reduction in
IL-10 amounts, whereas colons ofNiacr1/mice exhibited a se-
vere impairment of IL-10 production (Figure 4G). Expression of
several other genes that inhibit colitis and colon carcinogenesis
such as Tgfb1, Tgfb2, Tgfbr1, and Tgfbr2 was also drastically
reduced in colons of Niacr1/mice compared to WT mice after
AOM+DSS treatment (Figure S4G). In line with defective IL-18
production by colonic epithelium, colons of untreated Niacr1/
animals expressed significantly decreased amount of IL-18
compared to those of WT counterparts. Compared to untreated
animals, IL-18 expression was higher in colons of WT mice after
AOM+DSS treatment. In contrast, IL-18 amounts in colons of
Niacr1/ mice were drastically decreased compared to colons
of WT mice after AOM+DSS treatment (Figure 4G). Reduction in
IL-18 production was not due to defective inflammasome activa-
tion because colons and sera of AOM+DSS-treated Niacr1/
mice contained higher amounts of IL-1b (Figures S4F and S4H).
Increased amounts of IL-17 are associated with colonic inflam-
mation. Consistent with hyperproduction of IL-17 by colonic
CD4+ T cells, colons of untreated and AOM+DSS-treated
Niacr1/ mice expressed higher amounts IL-17 compared to
their WT counterparts (Figure 4G). Amounts of other cytokines
that promote colonic inflammation and carcinogenesis such as
Il1a, IL-6, CXCL1, CCL2, and IL-1bwere alsomarkedly increased
in colons ofNiacr1/mice after AOM+DSS treatment compared
to their WT counterparts (Figures S4G and S4H). Taken together,
these data demonstrate that an imbalance in the production of
anti-inflammatory molecules versus proinflammatory molecules
in favor of the latter increases the susceptibility of Niacr1/
mice to colonic inflammation.
GPR109a Deficiency Promotes Inflammation-Induced
as well as ApcMin/+-Driven Colon Carcinogenesis
We asked whether Niacr1/ mice are more susceptible to
development of colon cancer. In colons of untreated WT and
Niacr1/ mice, 80% and 20% of the crypts contained prolifer-
ating cells in lower 1/3 and 2/3 compartments, respectively. After
AOM+DSS treatment, in colon of WT mice, 53% and 47% of
crypts showed proliferating cells in their lower 1/3 and 2/3 com-
partments, respectively, and no crypt showed proliferation along
its full length. In contrast, 33% of crypts in colons of AOM+DSS-
treated Niacr1/ mice showed proliferating cells all along its
entire length (Figures S5A and S5B). Expression of cyclin-D1,
cyclin-B1, and cyclin-dependent kinase 1, which promote devel-
opment of colon cancer, was highly increased in colons ofImmunity 40, 128–139, January 16, 2014 ª2014 Elsevier Inc. 131
Figure 2. Butyrate and Niacin Induce Anti-inflammatory Properties in DCs and Macrophages in a Gpr109a-Dependent Manner
(A) Foxp3 expression by OT-II CD4+CD25 T cell differentiated in the presence of TGF-b1, IL-2, and cognate peptide with colonic LP CD11c+ (CD45+I-Ab+
CD11c+) and CD11b+ (CD45+I-Ab+CD11b+) cells from WT or Niacr1/ mice.
(B) OT-II CD4+CD25 T cells differentiated as described in (A) were restimulated with anti-CD3 and anti-CD28 antibodies. One day later, IL-10 and IL-17 in culture
supernatants were quantified by ELISA.
(C) Expression of Il10, Il6, and Aldh1a1 by colonic LP DCs and macrophages isolated from WT and Niacr1/ mice was quantified by qPCR.
(D) Sorted splenic DCs were cultured with butyrate or niacin. Two days later, cells were harvested, and expression of Il10 and Aldh1a1 was measured by qPCR.
(E) Naive OT-II CD4+CD25 T cells were differentiated with butyrate- or niacin-treated splenic DCs from indicated mice as described in (A). Shown is the FoxP3
expression by differentiated CD4+ T cells.
(legend continued on next page)
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Figure 3. Gpr109a Is Required for Butyrate- and Niacin-Mediated
IL-18 Induction
(A) Induction of IL-18 in neonatal colon. Colons of 6-day-old WT or Niacr1/
mice were cultured in medium with or without butyrate or niacin for 24 hr, and
Il18 mRNA was quantified by qPCR (n = 3).
(B) Expression of IL-18 mRNA and protein in colonic epithelial cells isolated
from WT or Niacr1/ mice were quantified by qPCR and ELISA, respectively
(n = 3).
(C) One day after oral administration of butyrate or niacin in vivo, expression of
IL-18 in colonic epithelium of WT or Niacr1/ mice was quantified (n = 3).
Error bars represent SD of mean. A representative of three independent
experiments is shown. See also Figure S3.
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Butyrate/Niacin Receptor Gpr109a in Colonic HealthNiacr1/ mice after AOM+DSS regime. In contrast, expression
of tumor suppressors Slc5a8, Msh2, and Msh3 were decreased
in colons of AOM+DSS-treated Niacr1/mice compared to WT
mice (Figure S5C). At the end of the AOM+DSS treatment
regime, colons of Niacr1/ mice showed increased number of(F)WT andNiacr1/micewere treatedwith antibiotics in the presence or absence
expression by colonic CD4+ T cell was analyzed.
The numbers in (A), (E), and (F) represent percentage of positive cells in indicated
independent experiments is shown. See also Figure S2.large polyps (22.8 ± 4.0 polyps/mouse) compared to those of
WTmice (2.3 ± 1.8 polyps/mouse) (Figures 5A–5C). Furthermore,
at completion of experiment, Niacr1/ animals also exhibited
anemia (Figure S5D). Mutations in adenomatous polyposis coli
(APC) gene cause an inherited form of colon cancer in humans.
Because IL-10 and Treg cells suppress whereas IL-17 enhances
colon carcinogenesis in ApcMin/+ mice (mice expressing a point
mutation in one copy of Apc gene) (Erdman et al., 2005; Griven-
nikov et al., 2012), we also analyzed ApcMin/+-driven intestinal
and colon carcinogenesis in Niacr1/ mice. At 3 months of
age, Niacr1/ApcMin/+ mice had strikingly more polyps in the
colon and small intestine than did ApcMin/+ mice (Figures 5D
and 5E). These data from two different animal models demon-
strating accelerated progression of colon carcinogenesis upon
deletion of Niacr1 provide strong evidence for the tumor-sup-
pressive role of this receptor in colon.
Gpr109a Expressed in Immune Cells as well as in
Colonic Tissue Is Necessary for Protection against
Colitis and Colon Carcinogenesis
To address the role of hematopoietic versus nonhematopoietic
cells expressing Gpr109a, reciprocal bone marrow (BM) chi-
meras between WT and Niacr1/ mice were generated and
subjected to AOM+DSS treatment. Gpr109a expressed in he-
matopoietic cells played a critical role in AOM+DSS-induced
colonic inflammation and carcinogenesis because a WT or
Niacr1/ host that receivedNiacr1/BMexhibited significantly
more AOM/DSS-induced weight loss, diarrhea, and colonic
polyps than corresponding recipients of WT BM cells (Figures
6A–6C). Similarly, Gpr109a expressed in nonhematopoietic cells
was also important in AOM+DSS-induced colonic inflamma-
tion and carcinogenesis because Niacr1/ mice receiving WT
or Niacr1/ BM cells developed more severe weight loss, diar-
rhea, and colon carcinogenesis than did a corresponding
WT host receiving the same BM cells (Figures 6A–6C). The
contribution by nonhematopoietic Gpr109a was quantitatively
greater than that by immune cell Gpr109a because the WT/
Niacr1/ group developed more colonic polyps and showed
more weight loss and diarrhea than did the Niacr1/ /WT
group (p < 0.004). These data demonstrate that Gpr109a
expressed by both hematopoietic and nonhematopoietic cells
is necessary for effective protection against colonic inflamma-
tion and colon cancers.
Activation of Gpr109a Suppresses Colonic Inflammation
and Carcinogenesis in the Absence of Gut Microbiota or
Dietary Fiber
We then examined the relevance of niacin, a pharmacologic
agonist for GPR109A, to colonic inflammation. For this, we first
depleted gut microbiota with antibiotics, which reduces the pro-
duction of butyrate, the endogenous agonist for GPR109A.
Antibiotic treatment resulted in >300-fold reduction in aerobic
and anaerobic bacterial counts in the stool (data not shown).
Antibiotic treatment increased DSS-induced weight loss,of niacin in drinking water. Four weeks later, colons were harvested and FoxP3
area. Error bars represent SD of mean (n = 2–3). A representative of at least two
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Figure 4. Increased Susceptibility of
Niacr1–/– Mice to Colonic Inflammation
(A) Experimental paradigm for induction of colonic
inflammation and inflammation-associated colon
cancer in mice; azoxymethane (AOM) by intra-
peritoneal injection; DSS in drinking water. At days
20 and 70, colons of mice were analyzed for
inflammation and cancer, respectively.
(B–D) Change in body weight, diarrhea, and rectal
bleeding of WT and Niacr1/ mice subjected to
AOM+DSS (nR 4).
(E) Representative images of H&E-stained colonic
sections from untreated or AOM+DSS-treated
(20th day) WT and Niacr1/ mice (original magni-
fication, 2003).
(F) Claudin-3 staining of colonic sections from
untreated (UT) or AOM+DSS-treated (20th day) WT
and Niacr1/ mice (original magnification, 2003).
(G) IL-10, IL-17, and IL-18 levels in colons of WT
and Niacr1/ mice before and after AOM+DSS
treatment (n = 5). Error bars represent standard
deviation of mean.
Values are mean ± SD or representative of at least
two independent experiments. See also Figure S4.
Immunity
Butyrate/Niacin Receptor Gpr109a in Colonic Healthdiarrhea, and bleeding in WT mice (Figures 7B and S6A).
Consistent with increased inflammation, we found that antibi-
otic treatment increased the number of polyps (8.2 ± 2.2
polyps/mouse with antibiotics; 1.6 ± 1.5 polyps/mouse without
antibiotics) in WT mice (Figures 7C and 7D). We then tested
whether administration of niacin protects antibiotic-treated
mice against colonic inflammation and carcinogenesis. Niacin
was added to drinking water along with antibiotic cocktail.
Niacin ameliorated AOM+DSS-induced weight loss, diarrhea,
and bleeding and reduced colon cancer development in antibi-
otic-treated WT mice (Figures 7B–7D and S6A). Consistent with
a role of niacin in IL-18 induction, the protective effect of niacin
in DSS-induced weight loss and diarrhea in antibiotic-treated
Il18/ mice was significantly blunted (Figure S6B). Niacin did
not alter the development of weight loss, diarrhea, rectal
bleeding, and colon cancer in antibiotic-treated Niacr1/
mice, suggesting an essential role of Gpr109a in niacin-medi-
ated promotion of colonic health (Figures 7B–7D and S6A). Anti-
biotic treatment reduced colonic inflammation and number of
polyps in Niacr1/ mice. This may be due to the presence of
altered colitogenic gut microbiota in Niacr1/ animals.
Increased representation of Prevotellaceae and TM7 groups
of bacteria are associated with enhanced risk of colitis in
IL-18-deficient mice (Casp1/, Asc/, Nlrp6/, or Il18/)
(Elinav et al., 2011). We found that feces of Niacr1/ mice ex-
hibited increased representation of Prevotellaceae and TM7
groups of commensal bacteria compared to WT mice (Fig-134 Immunity 40, 128–139, January 16, 2014 ª2014 Elsevier Inc.ure S6C). Bacteroides and Bacillus
groups of bacteria were present in com-
parable numbers in feces of both WT and
Niacr1/ mice. To test whether Gpr109a
deficiency promotes preferential accu-
mulation of Prevotellaceae and TM7
bacterial groups in their intestines inde-
pendent of parental contribution, we per-formed similar studies with fecal samples from littermates of
Niacr1+/ and Niacr1/ genotypes. We observed that feces
from Niacr1/ mice contained significantly more Prevotella-
ceae and TM7 bacteria than did feces from Niacr1+/ littermates
(Figure S6D). This provides evidence for significant alterations in
relative abundance of indicated microbial species in the colons
of Niacr1/ mice and explains the reduction of colonic inflam-
mation and colon carcinogenesis by antibiotic treatment in
Niacr1/ animals (Figures 7B–7D and S6A). Both exogenously
administered rIL-10 and rIL-18 were able to reduce AOM+DSS-
induced weight loss, diarrhea, and colon carcinogenesis in
Niacr1/ mice (Figures 7E and 7F).
Antibiotic treatment reduces the number of colonic polyps in
mice with Apc mutation, implying a cancer-promoting role of
gut microbiota in this model (Grivennikov et al., 2012; Li
et al., 2012). Our data indicate that gut microbial metabolite
butyrate and hence gut microbiota reduce colon carcinogen-
esis in ApcMin/+ mice. We hypothesized that gut microbiota
has both cancer-promoting and -suppressing effects in
ApcMin/+ mice, and microbiota-depleted animals show the bal-
ance between cancer-promoting and -suppressing properties
of gut microbiota. To define the protective role of Gpr109a in
promoting colonic health through butyrate and gut microbiota,
we fed ApcMin/+ mice and Niacr1/ApcMin/+ mice with fiber-
free (FF) diet, which eliminates butyrate production in colon.
Figures 7G and 7H show that ApcMin/+ mice fed FF-diet had
significantly increased number of colonic polyps, which was
Figure 5. Increased Susceptibility of
Niacr1–/– Mice to Colon Cancer
(A) Representative photographs of dissected
colons from WT and Niacr1/ mice on day 70
after animals were treated with AOM+DSS as
described in Figure 4A.
(B and C) Number (B) and size distribution (C) of
colonic polyps induced by AOM+DSS treatment in
WT and Niacr1/ mice (n = 6).
(D) Representative photographs of dissected
colons of 3-month-old ApcMin/+ and Niacr1/
ApcMin/+ mice.
(E) Number of polyps in colons and small intestines
of ApcMin/+ and Niacr1/ApcMin/+ mice (n = 4).
Values are mean ± SD or representative of two
independent experiments. See also Figure S5.
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the presence or absence of niacin did not affect development
of colonic polyps in Niacr1/ApcMin/+ mice. Collectively, these
data clearly indicate that Gpr109a agonists suppress develop-
ment of colon cancer. Butyrate, the endogenous Gpr109a
agonist in colon, is produced after fermentation of dietary fiber
by commensal bacteria. Therefore, the data presented here
suggest a role of Gpr109a in suppression of colonic inflamma-
tion and carcinogenesis by butyrate-producing commensals
and dietary fibers.
DISCUSSION
The current study defines an essential role of Gpr109a in the
suppression of colonic inflammation and carcinogenesis. Com-
mensals induce Treg cells and IL-10-producing T (Tr1) cells in
colon (Atarashi et al., 2011; Geuking et al., 2011; Mazmanian
et al., 2008; Round and Mazmanian, 2010). They also induce
IL-10 expression in colonic DCs and macrophages, which
promote differentiation of Tr1 cells (Jeon et al., 2012; Ueda
et al., 2010). Our studies provide a molecular mechanism
by which the commensals elicit these effects. The bacterial
metabolite butyrate functions as a messenger between the
commensals and the host. This SCFA induces expression of
anti-inflammatory molecules in macrophages and DCs and
enables them to support differentiation of Treg and IL-10-
producing T cells. The present study also implicates a tumor-
suppressive role of Gpr109a-butyrate signaling in colon and
suggests that commensals in the gut provide protection to
the host not only against colonic inflammation but also
against colon cancer. Our conclusion that butyrate is respon-
sible, at least partly, for the actions of gut microbiota on the
host colon with regard to suppression of inflammation and
carcinogenesis is congruent with previous findings that the
frequency of butyrate-producing bacteria and rate of butyrate
production are greatly diminished in the colon during ulcerative
colitis and colon cancer (Frank et al., 2007; Wang et al., 2012).
Butyrate enemas decrease colonic inflammation in ulcerativeImmunity 40, 128–139colitis (Hamer et al., 2008). The present
studies also highlight the biological
significance of dietary fiber and its rele-
vance to butyrate production. Dietaryfiber suppresses colonic inflammation and colorectal cancer
(Davis and Milner, 2009; Hamer et al., 2008). The most impor-
tant aspect of the present studies is the identification of
Gpr109a as one of the mediators of the biological effects of
butyrate.
Niacin is a vitamin, which, when taken in pharmacolog-
ical doses, suppresses atherosclerosis by acting as a
GPR109A agonist in immune cells. At these high doses, niacin
is likely to reach the colon at concentrations high enough
to exert GPR109A-dependent effects. Therefore, the present
studies suggest that pharmacological doses of niacin may
have anti-inflammatory and tumor-suppressive effects in the
colon.
Although it has been known for decades that the commensal
metabolite butyrate suppresses inflammation and carcino-
genesis in colon, the exact identity of molecular target(s) of
butyrate in this process remained elusive. The present studies
identify Gpr109a as an important mediator of butyrate effects
in colon and also as a critical molecular link between colonic
bacteria and dietary fiber and the host. These findings
have important implications for prevention as well as treatment
of inflammatory bowel disease and colon cancer and suggest
that under conditions of reduced dietary fiber intake and/or
decreased butyrate production in colon, pharmacological
doses of niacin might be effective to maintain GPR109A
signaling and consequently protect colon against inflammation
and carcinogenesis.EXPERIMENTAL PROCEDURES
Mice
Age-matched conventional and germ-free mice (Swiss Webster strain) were
obtained from Taconic Farms and used for experiments on day of arrival.
Il18/ and ApcMin/+ mice on C57BL/6 background were obtained from
Jackson Laboratory. Fiber-free diet (TD00278) was from Harlan Laboratories.
Niacr1+/ApcMin/+ mice were derived from intercross of Niacr1/ mice and
ApcMin/+mice.Niacr1+/ApcMin/+micewere bredwithNiacr1/mice to obtain
Niacr1/ApcMin/+ mice. All animal procedures were approved by the Institu-
tional Animal Care and Use Committee, Georgia Regents University., January 16, 2014 ª2014 Elsevier Inc. 135
Figure 6. Role of Gpr109a Expressed in Hematopoietic and Non-
hematopoietic Cells in Regulation of Colitis and Colitis-Associated
Colon Cancer
Reciprocal bone marrow chimeras of WT and Niacr1/ mice were subjected
to AOM+DSS-induced model of colitis-associated colon cancer.
(A) Weight loss and diarrhea after the first cycle of DSS (nR 4). Single asterisk
(*) indicates significant difference between WT/ Niacr1/ and Niacr1//
Niacr1/ group for weight loss (p < 0.05) and diarrhea (p < 0.02).
Double asterisk (**) indicates significant difference between WT / WT and
Niacr1// WT group for weight loss and diarrhea (p < 0.02).
(B) Representative photographs of dissected colons from bone marrow
chimeric mice.
(C) Tumor burden in bone marrow chimeras subjected to AOM+DSS-induced
colon cancer (nR 4).
Error bars represent ±SD of mean. A representative of two independent
experiments is shown.
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Antibodies against mouse CD4 (clone GK1.5), CD45 (clone 104), Foxp3 (clone
FLK-16 s), IL-10 (clone JES5-16E3), IL-17 (clone eBio17B7), CD11b (cloneM1/
70), CD11c (clone N418), I-Ab (clone 25-9-17), CD90 (clone 53-2.1), CD19
(clone SJ25C1), and Gr1 (clone RB6-8C5) and against human CD3 (clone
UCHT1), CD14 (61D3), CD123 (6H6), and CD56 (CMSSB) were from
eBioscience. Anti-human GPR109A (clone 245106), anti-Ki67 (clone TEC-3),
and anti-claudin3 (34-1700) were from R&D Systems, Dako, and Life Technol-
ogies, respectively.
Cell Isolation and Analysis
B cells (CD19+), T cells (Thy1.1+), macrophages (CD11b+CD11c), dendritic
cells (CD11c+CD11b), and CD4+CD25 T cells from spleens and CD45+
I-Ab+CD11c+ (DCs) or CD45+I-Ab+CD11b+ (macrophages) cells from colonic
LP were sorted with MoFlo (Dakocytomation) or FACS Aria Flow cytometers
(BD Biosciences). Alternatively, splenic CD11c+ or CD11b+ cells were sorted
with CD11b or CD11c antibodies coupled to magnetic beads (Miltenyi Bio-
tec). For isolation of colonic epithelium, washed and everted colons were
incubated in Hanks balanced salt solution (HBSS) containing 2 mM EDTA
at 37C with gentle shaking. Supernatants were centrifuged and pellets
were resuspended in 40% percoll and centrifuged. The cells on top layer
were collected and used as colonic epithelium. For lamina propria lympho-
cytes, colons and small intestines were opened and shaken with HBSS
containing 2 mM EDTA at 37C to remove epithelial cells. After that, pieces
of colon or small intestine were incubated with collagenase D (1 mg/ml)136 Immunity 40, 128–139, January 16, 2014 ª2014 Elsevier Inc.and DNase (0.1 mg/ml) for 20 min. The cell suspension was collected,
washed, and stained with antibodies specific for mouse CD4 and Foxp3
and analyzed by FACS. In some experiments, mononuclear cells from colonic
LP or spleen of WT and Niacr1/ mice were cultured with phorbol myristate
acetate plus ionomycin in the presence of GolgiStop and Golgiplug for 5 hr.
Cells were fixed and stained for CD4, IL-10, and IL-17. Peripheral blood
mononuclear cells were obtained with institutional approval from Institutional
Review Boards, Georgia Regents University.
Cell Cultures
Sorted colonic LP CD45+I-Ab+CD11c+ or CD45+I-Ab+CD11b+ cells were
cultured with naive OT-II (CD4+CD25) T cells in the presence of egg albumin
peptide (ISQVHAAHAEINEA) (0.5 mg/ml), TGF-b1 (1 ng/ml), and IL-2 (5 ng/ml).
After 4 days, cells were harvested and stained for CD4 and FoxP3. Alterna-
tively, cells were rested overnight and restimulated with plate-bound anti-
CD3 (1 mg/ml) and anti-CD28 (1 mg/ml). After 24 hr, supernatants was collected
and analyzed for IL-10 and IL-17a by ELISA. Splenic CD11c+ (DCs) and
CD11b+ (macrophages) were cultured (105 cells/well) in the presence or
absence of butyrate (0.5 mM) or niacin (0.5 mM). After 2 days, cells were har-
vested and analyzed for IL-10 and Aldh1a expression or tested for their ability
to induce differentiation of naive OT-II CD4+ T cells as above. In some exper-
iments, retinoic acid receptor (RAR) inhibitor LE135 was used (1 mM).
Bone Marrow Chimeras
WT (CD45.1) or Niacr1/ (CD45.2) mice were irradiated (900 rads) and
injected intravenously with donor bone marrow cells (2 3 106 cells/mouse).
Reconstitution was confirmed by staining for donor-specific CD45 allele
(CD45.1 versus CD45.2) in blood. Two months after reconstitution, mice
were used for colonic inflammation-associated colon cancer experiments.
Antibiotics and Niacin Treatment
Micewere given a cocktail of antibiotics (0.2 mg/ml of gentamicin, 0.15 mg/ml of
ciprofloxacin, 2 mg/ml streptomycin, and 1 mg/ml bacitracin) in drinking water
at the indicated period of time. Where indicated, antibiotic cocktail was sup-
plemented with 25mMof niacin. For IL-18 induction assays, micewere treated
with butyrate or niacin (25 mM) as described (Kalina et al., 2002).
Induction of Colonic Inflammation and Inflammation-Associated
Colon Cancer
Inflammation-associated colon cancer was induced by intraperitoneal injec-
tion of azoxymethane (10 mg/kg body weight). Seven days later, DSS (36–
50 kDa) was added in a cyclic manner to drinking water at indicated doses.
Some mice were also given rIL-10 or rIL-18 intraperitoneally (50 ng/mouse)
at indicated points. Mice were monitored for weight changes, diarrhea, and
rectal bleeding. Diarrhea was scored as (0) normal stool, (1) soft but formed
pellet, (2) very soft pellet, (3) diarrhea (no pellet), or (4) dysenteric diarrhea.
Rectal bleeding was recorded as (0) no bleeding, (2) presence of occult blood
in stool, or (4) gross macroscopic bleeding.
Histopathology and Immunohistochemistry
Sections (5 mm) from formalin-fixed and paraffin-embedded colons or polyps
were placed onto glass slides. H&E-stained sections were blindly scored for
severity of colonic inflammation. The degree of inflammation was scored as
follows: (0) no inflammation, (1) mild inflammation or prominent lymphoid
aggregates, (2) moderate inflammation, (3) moderate inflammation associated
with crypt loss, and (4) severe inflammation with crypt loss and ulceration.
Crypt destruction was graded as follows: (0) no destruction, (1) 1%–33% of
crypts destroyed, (2) 34%–66% of crypts destroyed, and (3) 67%–100% of
crypts destroyed. The individual scores from inflammation and crypt damage
were summed to derive histological score for colonic inflammation (maximum
score 7). For immunohistochemistry, sections were deparaffinized with
xylene and antigen retrieval was performed with target antigen retrieval
solution (Dako). The staining was visualized with Vectstain ABC kit and
diaminobenzidine.
Quantitative Real-Time PCR
cDNA was synthesized from 2 mg of total RNA by Superscript III reverse tran-
scription system (Invitrogen). qPCR was performed with SYBR green PCRmix
Figure 7. Niacin Suppresses Colonic
Inflammation and Carcinogenesis in
Absence of Gut Microbiota and Dietary
Fiber via Gpr109a
(A) Experimental paradigm for antibiotic treatment
(gentamicin sulfate, ciprofloxacin, streptomycin,
and bacitracin in drinking water) and niacin
administration to mice in the AOM+DSS-induced
colon cancer model.
(B) Weight loss in WT and Niacr1/ mice treated
with antibiotics in the presence or absence of
antibiotics and subjected to AOM+DSS as in (A).
(C) Tumor burden in WT and Niacr1/ mice under
various treatment conditions (nR 4).
(D) Representative photographs of dissected
colons of WT and Niacr1/ mice subjected to
various treatments as described in (A).
(E) Niacr1/ mice were treated as in Figure 4A.
Some mice also received rIL-10 or rIL-18 intra-
peritoneally (50 ng/mouse/injection) starting
day 2 and every alternate day till day 60. Shown
are the weight loss and diarrhea during first cycle
of DSS.
(F) Tumor burden on day 70 in Niacr1/ mice
treated as described in (E) (n = 4).
(G) Two-month-old ApcMin/+ and Niacr1/
ApcMin/+ mice were fed with dietary fiber contain-
ing normal chow (FC) or fiber-free (FF) chow. Some
mice in FF diet group also received niacin in
drinking water ad libitum. Five weeks later, mice
were sacrificed and colonic polyps were counted
(n = 2–5). *p < 0.007.
(H) Representative photographs of dissected
colons from mice subjected to experimental pro-
tocol described in (G).
Values represent mean ± SD or representative of
at least two independent experiments. See also
Figure S6.
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Butyrate/Niacin Receptor Gpr109a in Colonic Healthand StepOnePlus machine (Applied Biosystems). PCR primers are listed in
Table S1. Gapdh was used as internal control.
ELISA
Colonic tissue or colonic epithelium extracts were prepared in PBS containing
0.1%NP-40 and protease inhibitors (Thermo Fisher Scientific). ELISAwas per-
formed with antibody pairs for IL-6, IL-1b, and IL-17. ELISA kits for IL-18
and Ccl2 were from R&D systems and eBioscience, respectively. Cxcl1 was
quantified with a kit from Peprotech. Serum amyloid A was detected via Kit
from Immunology Consultants Laboratory.
Measurement of Intestinal Permeability
Mice were given fluorescein isothiocyanate (FITC)-dextran by oral gavage
at a dose of 0.5 mg/g of body weight. Four hours later, mice were
bled and FITC-dextran was quantified in the serum via a fluorescence
spectrophotometer.
Myeloperoxidase Activity
Pieces of colon (100 mg weight) were homogenized in phosphate buffer
(20 mM [pH 7.4]) and centrifuged. Pellet was resuspended in phosphate bufferImmunity 40, 128–139(50 mM [pH 6.0]) containing 0.5% hexadecyltrime-
thylammonium bromide (Sigma). The sample was
freeze-thawed, sonicated followed by warming to
60C for 2 hr, and centrifuged. Redox reaction of
3,30,5,50-tetramethylbenzidine (Sigma) by super-
natant was used to determine myeloperoxidase(MPO) activity. Reaction was terminated with 2N HCl and absorbance was
read at 450 nm.
Organ Culture
Colons from7-day-oldpupswereopened,cut into0.5cmpieces,andcultured
with butyrate (0.5mM) or niacin (1mM) for 24 hr. The tissues were then used for
analysis of Il18 mRNA by qPCR. For DSS-treated animals, colon segments
(100 mg weight) were chopped into smaller pieces (1–2 mm) and cultured in
medium containing penicillin and streptomycin. Twenty-four hours later, super-
natants were collected and cytokines were measured by ELISA.
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